Morgan Stanley Issues Pessimistic Forecast for Danaher (NYSE:DHR) Stock Price

Danaher (NYSE:DHR) had its target price decreased by investment analysts at Morgan Stanley from $270.00 to $255.00 in a report released on Wednesday,MarketScreener reports. Morgan Stanley’s target price would indicate a potential upside of 42.68% from the stock’s current price.

A number of other equities analysts have also weighed in on DHR. UBS Group decreased their target price on Danaher from $270.00 to $250.00 and set a “buy” rating for the company in a research report on Wednesday. The Goldman Sachs Group decreased their target price on Danaher from $265.00 to $230.00 and set a “buy” rating for the company in a research report on Monday, April 13th. KeyCorp reissued an “overweight” rating on shares of Danaher in a research report on Thursday, January 29th. JPMorgan Chase & Co. decreased their target price on Danaher from $275.00 to $245.00 and set an “overweight” rating for the company in a research report on Wednesday. Finally, Barclays decreased their target price on Danaher from $250.00 to $230.00 and set an “overweight” rating for the company in a research report on Tuesday, April 14th. Seventeen investment analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the stock. According to MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $242.45.

Danaher Price Performance

Shares of NYSE:DHR opened at $178.72 on Wednesday. Danaher has a fifty-two week low of $175.00 and a fifty-two week high of $242.80. The business has a 50-day simple moving average of $196.45 and a two-hundred day simple moving average of $214.10. The company has a debt-to-equity ratio of 0.33, a quick ratio of 1.51 and a current ratio of 1.87. The firm has a market cap of $126.49 billion, a price-to-earnings ratio of 34.57, a price-to-earnings-growth ratio of 2.50 and a beta of 0.95.

Danaher (NYSE:DHR) last issued its earnings results on Tuesday, April 21st. The conglomerate reported $2.06 earnings per share for the quarter, topping analysts’ consensus estimates of $1.94 by $0.12. Danaher had a return on equity of 10.91% and a net margin of 14.89%.The business had revenue of $5.95 billion during the quarter, compared to analyst estimates of $6 billion. During the same quarter in the previous year, the firm earned $1.88 EPS. Danaher’s revenue was up 3.7% on a year-over-year basis. Danaher has set its FY 2026 guidance at 8.350-8.550 EPS. On average, analysts expect that Danaher will post 8.4 earnings per share for the current year.

Insider Activity

In other Danaher news, EVP Gregory M. Milosevich sold 1,320 shares of the business’s stock in a transaction dated Thursday, February 19th. The stock was sold at an average price of $208.01, for a total transaction of $274,573.20. Following the completion of the sale, the executive vice president directly owned 5,099 shares in the company, valued at $1,060,642.99. The trade was a 20.56% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. 10.80% of the stock is currently owned by corporate insiders.

Institutional Inflows and Outflows

A number of hedge funds have recently made changes to their positions in DHR. JPL Wealth Management LLC bought a new position in shares of Danaher during the 3rd quarter valued at approximately $25,000. Elevated Capital Advisors LLC bought a new position in shares of Danaher during the 4th quarter valued at approximately $26,000. WFA of San Diego LLC bought a new position in shares of Danaher during the 2nd quarter valued at approximately $26,000. ANTIPODES PARTNERS Ltd bought a new position in shares of Danaher during the 3rd quarter valued at approximately $27,000. Finally, Hilton Head Capital Partners LLC bought a new position in shares of Danaher during the 4th quarter valued at approximately $27,000. 79.05% of the stock is currently owned by institutional investors.

Trending Headlines about Danaher

Here are the key news stories impacting Danaher this week:

• Positive Sentiment: Q1 EPS beat and slight raise to FY EPS range — Danaher beat non‑GAAP EPS estimates ($2.06 vs. consensus) and nudged full‑year adjusted EPS guidance higher, which supports earnings visibility. Earnings Call Highlights
• Positive Sentiment: Bioprocessing momentum and M&A strategy remain drivers — management highlighted strength in bioprocessing and the acquisition pipeline as long‑term growth levers. Q1 Deep Dive
• Neutral Sentiment: Large euro‑denominated senior‑notes offering (~€2.98B net proceeds) — the deal finances operations and transactions but increases liabilities; market reaction depends on how proceeds are used. Notes Offering
• Neutral Sentiment: Masimo acquisition: longer‑term optionality vs. near‑term integration/earnings pressure — analysts note the deal adds strategic upside but may weigh on near‑term returns and capital allocation. Masimo Analysis
• Negative Sentiment: $172.5M shareholder settlement over post‑pandemic demand disclosures — a material cash charge and reputational headwind that increases near‑term litigation/expense risk. Settlement Report
• Negative Sentiment: Revenue miss and Diagnostics softness weighed on the print — core revenue growth was modest and Diagnostics showed weakness (lighter respiratory season at Cepheid), which undercut the EPS beat. Revenue/Segment Notes
• Negative Sentiment: Multiple analyst price‑target cuts (Morgan Stanley, JPMorgan, Wells Fargo, Guggenheim, UBS among others) — downgrades and lower targets increase downside pressure and reduce near‑term analyst support. Morgan Stanley PT Cut

Danaher Company Profile

Danaher Corporation (NYSE: DHR) is a global science and technology company that designs, manufactures and markets products and services for the life sciences, diagnostics, and environmental and applied markets. The company organizes its operations into business segments focused on Life Sciences, Diagnostics, and Environmental & Applied Solutions, supplying instruments, reagents, software and related services that support research, clinical testing, biopharmaceutical development, and industrial and environmental monitoring.

Products and services in Danaher’s portfolio include analytical and diagnostic instruments, laboratory consumables and reagents, digital and software solutions for workflow and data management, field and industrial monitoring equipment, and service and maintenance programs.